Switch theme
Sign up to access all valuation multiples
Gr. Sarantis SA is a consumer products manufacturer that offers cosmetics, including aftershave lotions and deodorants with brands such as Adidas and C-THRU; household products including food packaging, cleaning, and shoe care products of such brands as Sanitas and Camel; and health & care products & para pharmaceutical products including vitamins and food supplements, pregnancy and ovulation tests, and sun care products, and luxury cosmetics, including fragrance, treatment, and makeup products under its brands and various other brands. It operates in segments: Beauty / Skin Care / Sun Care, Personal Care, Home Care Solutions, Private Label, Strategic Partnerships and Other Sales. The geographical segments are Greece, Ukraine, Poland, Romania, Czech, Hungary, Slovakia, and others.
1964
3.1K+
LTM Revenue $721M
LTM EBITDA $102M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sarantis Group has a last 12-month revenue (LTM) of $721M and a last 12-month EBITDA of $102M.
In the most recent fiscal year, Sarantis Group achieved revenue of $699M and an EBITDA of $95.7M.
Sarantis Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sarantis Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $721M | XXX | $699M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $264M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 38% | XXX | XXX | XXX |
| EBITDA | $102M | XXX | $95.7M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $77.9M | XXX | $71.6M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $60.7M | XXX | $53.6M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $14.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Sarantis Group's stock price is EUR 14 (or $16).
Sarantis Group has current market cap of EUR 887M (or $1.0B), and EV of EUR 919M (or $1.1B).
See Sarantis Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.0B | XXX | XXX | XXX | XXX | $0.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Sarantis Group has market cap of $1.0B and EV of $1.1B.
Sarantis Group's trades at 1.5x EV/Revenue multiple, and 11.2x EV/EBITDA.
Equity research analysts estimate Sarantis Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sarantis Group has a P/E ratio of 17.0x.
See valuation multiples for Sarantis Group and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 10.5x | XXX | 11.2x | XXX | XXX | XXX |
| EV/EBIT | 13.7x | XXX | 15.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.0x | XXX | 19.3x | XXX | XXX | XXX |
| EV/FCF | 17.3x | XXX | 20.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSarantis Group's last 12 month revenue growth is 5%
Sarantis Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Sarantis Group's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sarantis Group's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sarantis Group and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sarantis Group acquired XXX companies to date.
Last acquisition by Sarantis Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Sarantis Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Sarantis Group founded? | Sarantis Group was founded in 1964. |
| Where is Sarantis Group headquartered? | Sarantis Group is headquartered in Greece. |
| How many employees does Sarantis Group have? | As of today, Sarantis Group has 3.1K+ employees. |
| Who is the CEO of Sarantis Group? | Sarantis Group's CEO is Mr. Ioannis K. Bouras. |
| Is Sarantis Group publicy listed? | Yes, Sarantis Group is a public company listed on ATH. |
| What is the stock symbol of Sarantis Group? | Sarantis Group trades under SAR ticker. |
| When did Sarantis Group go public? | Sarantis Group went public in 1994. |
| Who are competitors of Sarantis Group? | Similar companies to Sarantis Group include e.g. Acme United, EZZ Life Science, Lavipharm, SynBiotic. |
| What is the current market cap of Sarantis Group? | Sarantis Group's current market cap is $1.0B |
| What is the current revenue of Sarantis Group? | Sarantis Group's last 12 months revenue is $721M. |
| What is the current revenue growth of Sarantis Group? | Sarantis Group revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Sarantis Group? | Current revenue multiple of Sarantis Group is 1.5x. |
| Is Sarantis Group profitable? | Yes, Sarantis Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sarantis Group? | Sarantis Group's last 12 months EBITDA is $102M. |
| What is Sarantis Group's EBITDA margin? | Sarantis Group's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Sarantis Group? | Current EBITDA multiple of Sarantis Group is 10.5x. |
| What is the current FCF of Sarantis Group? | Sarantis Group's last 12 months FCF is $61.9M. |
| What is Sarantis Group's FCF margin? | Sarantis Group's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Sarantis Group? | Current FCF multiple of Sarantis Group is 17.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
